A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
NCT ID: NCT05089630
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
339 participants
INTERVENTIONAL
2021-10-14
2025-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
NCT00435396
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT04975893
Cytomegalovirus Vaccine in Healthy Participants
NCT00712634
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
NCT01986010
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pentamer(low)/gB(low)/Adjuvant Group
Participants receive the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
Pentamer (low)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (med)/gB(low)/Adjuvant Group
Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
Pentamer (med)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (med)/gB(med)/Adjuvant Group
Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
Pentamer (med)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (high)/gB(med)/Adjuvant Group
Participants receive the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
Pentamer (high)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Placebo Group
Participants receive placebo (saline) at 0,2 and 6 months and are followed up until end of study (Day 546).
Placebo (saline)
Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pentamer (low)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (med)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (med)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Pentamer (high)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Placebo (saline)
Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent obtained from the participant prior to performance of any study specific procedure.
* A healthy adult (woman or man), 18 to 50 years of age at the time of the first study intervention administration.
* Healthy participants as established by medical history and clinical examination before entering the study.
* Participants who are women of non-childbearing potential may be enrolled in the study.
* Participants who are women of child-bearing potential may be enrolled in the study, if the participant:
* has practiced adequate contraception for 30 days prior to study intervention administration, and
* has a negative pregnancy test on the day of study intervention administration and
* has agreed to continue adequate contraception during the entire treatment period and for 3 months after completion of the study intervention administration series.
* Participants who agree to take appropriate infection control measures to prevent becoming infected with SARS-CoV2 during the study.
* Participants who initially fail screening due to COVID-19 infection may be re-screened and included in the study, within the screening window period.
* Participants with signs/symptoms suggestive of active COVID-19 (i.e., fever, cough, etc.) should be isolated for the time period recommended by CDC since the signs/symptoms started, and symptoms have resolved.
* Participants with known COVID-19 positive contacts should be quarantined for the time period since exposure recommended by CDC since the exposure and the participant remains symptom free or COVID test negative.
* Participants who are diagnosed with COVID-19 may receive their subsequent CMVsu vaccination dose provided they have no fever, and their condition is considered stable by the investigator (e.g., there may be mild lingering cough, but no shortness of breath or difficulty breathing) within the original schedule.
* Participants who initially fail screening due to other active infections may be re screened within the screening window period and included in the study, if they no longer have signs or symptoms of active infection in the judgment of the site investigator.
* If a participant has equivocal results on CMV serodiagnostic screening test, they are permitted to be re-screened if within the 60-day screening window. Flexibility in safety blood evaluations will be permitted within the Schedule of activities time intervals.
Exclusion Criteria
* Known documented medical history of or viral hepatitis B or C infection.
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
* Any confirmed or suspected immunosuppressive or immunodeficient condition.
* Family history of congenital or hereditary immunodeficiency.
* History of or current autoimmune disease.
* Lymphoproliferative disorder or malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer).
* Hypersensitivity to latex.
* Major congenital defects
* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.
* Recurrent history or uncontrolled neurological disorders.
* Any hematological or biochemical abnormality.
* Any acute or chronic, clinically significant disease or pulmonary, cardiovascular, hepatic, or renal functional abnormalities.
* Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
* Participants with symptoms suggestive of active COVID-19 infection are excluded.
* Participants with known COVID-19 positive contacts within the past 14 days should be excluded for at least 14 days since the exposure and the participant remains symptom free.
* Any other clinical condition that, might pose additional risk to the participant due to participation in the study.
Prior/Concomitant therapy
* Any history of or planned receipt of a CMV vaccine other than the study intervention at any time point.
* Use of other investigational/non-registered product during the period beginning 30 days before the first dose, or their planned use during the study period.
* Planned administration of any vaccine not foreseen by the study protocol 30 days before and 30 days after each study vaccination administration any licensed influenza vaccine administered \> 15 days before/ after vaccination.
* In case of extraordinary emergency mass vaccination for an unforeseen public health threat the time period can be reduced if necessary, for that mass vaccination vaccine, which may be under emergency use authorization.
* COVID-19 vaccines should be given at least 30 days before or after administration of a GSK study vaccine. This interval can be reduced to \> 14 days, if emergency vaccination is recommended by public health authorities.
* Candidate COVID-19 vaccines are not allowed.
* Chronic administration of immunosuppressants or other immune-modifying drugs within 3 months prior to the vaccine dose. Inhaled and topical steroids are allowed.
* Administration of long-acting immune-modifying drugs at any time during the study period.
* Administration of immunoglobulins and/or any blood products during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period.
Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention
Other exclusions
* Pregnant or lactating women. If a woman becomes pregnant/lactating during the study, she will be excluded from subsequent vaccine doses but will be followed for safety.
* Women planning to become pregnant or planning to discontinue contraceptive precautions before 3 months after last study vaccination.
* Participants with known high exposure risk for CMV transmission, to enable distinction of true vaccine effect from natural infection during the study.
* Planned move to a location that will prohibit participating in the trial until study end.
* Participants with current chronic alcohol consumption and/or drug abuse as defined by Diagnostic and Statistical Manual of Mental Disorders 5th edition.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Hallandale, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Dearborn, Michigan, United States
GSK Investigational Site
Springfield, Missouri, United States
GSK Investigational Site
Lincoln, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Newark, New Jersey, United States
GSK Investigational Site
Secaucus, New Jersey, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Cedar Park, Texas, United States
GSK Investigational Site
Galveston, Texas, United States
GSK Investigational Site
Puyallup, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sanchez-Martinez ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y. CHO cells for virus-like particle and subunit vaccine manufacturing. Vaccine. 2024 Apr 11;42(10):2530-2542. doi: 10.1016/j.vaccine.2024.03.034. Epub 2024 Mar 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
209976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.